Abstract

Steroid-resistant asthma is often characterized by high levels of neutrophils and mixed TH2/TH17 immune profiles. Indeed, neutrophils are key drivers of chronic lung inflammation in multiple respiratory diseases. Their numbers correlate strongly with disease severity, and their presence is often associated with exacerbation of chronic lung inflammation. What factors drive development of neutrophil-mediated chronic lung disease remains largely unknown, and we sought to study the role of GM-CSF as a potential regulator in chronic asthma. Different experimental animal models of chronic asthma were used in combination with alveolar macrophage-reconstitution of global GM-CSF receptor knockout mice as well as cell-type-specific knockout animals to elucidate the role of GM-CSF signaling in chronic airway inflammation. We identify GM-CSF signaling as a critical factor regulating pulmonary accumulation of neutrophils. We show that although being not required for intrinsically regulating neutrophil migration, GM-CSF controls lung dendritic cell function, which in turn promotes T-cell-dependent recruitment of neutrophils to the airways. We demonstrate that GM-CSF regulates lung dendritic cell antigen uptake, transport, and TH2/TH17 cell priming in an intrinsic fashion, which in turn drives pulmonary granulocyte recruitment and contributes to development of airway hyperresponsiveness in chronic disease. We identify GM-CSF as a potentially novel therapeutic target in chronic lung inflammation, describing a GM-CSF-dependent lung conventional dendritic cell-T-cell-neutrophil axis that drives chronic lung disease.

Highlights

  • Steroid-resistant asthma is often characterized by high levels of neutrophils and mixed TH2/TH17 immune profiles

  • We show that GM-CSF drives antigen uptake, transport, and priming of TH2/TH17 cells in a Dendritic cell dLN (DC)-intrinsic manner and this promotes airway inflammation including recruitment of granulocytes as well as airway hyperresponsiveness (AHR)

  • We show that in the context of chronic asthmatic inflammation it is critically involved in driving recruitment of disease-exacerbating neutrophils and eosinophils, development of AHR, and chronic airway inflammation

Read more

Summary

Objective

What factors drive development of neutrophilmediated chronic lung disease remains largely unknown, and we sought to study the role of GM-CSF as a potential regulator in chronic asthma. Because of the complete lack of AMs in GMCSF4 or GM-CSF-receptor–deficient[6] animals, these mice develop strong pulmonary alveolar proteinosis (PAP), which has a profound impact on the lung microenvironment.[4] This has been a strong confounding factor in previous studies looking at the role of GM-CSF in pulmonary allergic inflammation in either ligand[7] or common b-chain–deficient animals.[8] In addition, neutralization of GM-CSF in a house dust mite (HDM) extract model reduced pulmonary eosinophilia and was associated with an impaired TH2 response, but the underlying mechanism was unclear.[2] In this context, we could recently show that reconstitution of a normal AM compartment in GM-CSF receptor alpha–deficient (Csf2ra2/2) mice can be used to prevent PAP, while still allowing investigation of GM-CSF receptor importance in pulmonary disease.[9] Using this approach, we identified that GM-CSF receptor signaling in eosinophils promotes their migration to the lung in a model of acute allergic asthma.[9] experimental animal models have focused on acute aspects of lung inflammation, which are driven by TH2/innate lymphoid cell (ILC) type 2 responses, the long-term chronic pathology characteristic of human patients with asthma remains underinvestigated.[10] in mice chronic asthma models have indicated that apart from TH2 immunity, TH17 responses and associated neutrophilia are hallmarks in chronic stages of the disease.[11] Neutrophilic asthma is often refractory to steroid treatment and from a clinical perspective the investigation of pathophysiological mechanisms in this context is highly warranted

METHODS
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call